Pioneering a new wave of oncology treatment

Immuno-oncology meets global science and big data

About EXUMA Biotech

EXUMA Biotech is a clinical-stage biotechnology company discovering and developing Chimeric Antigen Receptor (CAR)-T cell products for solid tumors.

CAR-T cell therapy has already delivered remarkable on-target responses to certain hematological malignancies through a complex manufacturing process. Through our tumor metabolism regulated (TMR) CAR-T platform, we are taking cellular therapies to the next step by harnessing the power of the immune system to target some of the most challenging solid tumor malignancies, and building CAR-T delivery platforms that may enable more patients to access cellular therapies in the future.

Same-day autologous CAR-T therapy

As part of our commitment to make CAR-T more accessible to earlier lines of therapy, we are developing best-in-class delivery solutions to address specific unmet needs in the cell therapy space.

Our current centralized process, “CCT3″, is a fresh-in, frozen-out 12 day process on a fully electronic batch record system.

Our next-generation rapid point-of-care, or “rPOC”, subcutaneous, same-day manufacturing platform is being developed to enable use in the outpatient setting. In the fight against cancer, our global teams are advancing this first of its kind autologous treatment that could make same-day CAR-T a reality for all cancer patients.

Innovation is at the core of our global network

From West Palm Beach to Grand Cayman to Shanghai: We are integrated over 12 hours of time zones because cancer never sleeps, and neither does the data.